Loading...
VolitionRX Ltd (VNRX) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown revenue growth, its financial performance remains weak with declining net income and EPS. Technical indicators are mixed, and there are no significant positive catalysts or trading signals to support a buy decision currently. A hold position is recommended until stronger signals or catalysts emerge.
The MACD histogram is positive and expanding, indicating a potential bullish momentum. However, the RSI is neutral at 58.857, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5), suggesting the stock is in a downtrend. Key support and resistance levels are Pivot: 0.216, R1: 0.251, S1: 0.181, R2: 0.273, S2: 0.159.

Revenue increased by 32.19% YoY in Q3 2025, and gross margin remains at 100%.
Net income dropped by -7.61% YoY, and EPS declined by -28.57% YoY. Analysts have downgraded the stock to Hold from Buy. No recent news or significant trading trends from hedge funds or insiders.
In Q3 2025, revenue increased to $627,277 (up 32.19% YoY), but net income dropped to -$5,378,358 (-7.61% YoY), and EPS fell to -0.05 (-28.57% YoY). Gross margin remained at 100%.
Maxim downgraded VolitionRX to Hold from Buy on 2025-12-03.